{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:31:41Z","timestamp":1780565501912,"version":"3.54.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008397","name":"Velux Fonden","doi-asserted-by":"publisher","award":["00025835"],"award-info":[{"award-number":["00025835"]}],"id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","award":["E-12825-01-12-01"],"award-info":[{"award-number":["E-12825-01-12-01"]}],"id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jamda.2022.06.010","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T05:26:15Z","timestamp":1657949175000},"page":"1926.e11-1926.e35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Scoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2662-4519","authenticated-orcid":false,"given":"Jonatan","family":"Kornholt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cille","family":"B\u00fclow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Mette S.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckart","family":"Pressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonny S.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2022.06.010_bib1","series-title":"Multimorbidity","year":"2016"},{"key":"10.1016\/j.jamda.2022.06.010_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jamda.2022.06.010_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/CLEP.S153458","article-title":"The epidemiology of polypharmacy in older adults: register-based prospective cohort study","volume":"10","author":"Morin","year":"2018","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jamda.2022.06.010_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/pds.1984","article-title":"Adverse drug events in the outpatient setting: an 11-year national analysis","volume":"19","author":"Bourgeois","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jamda.2022.06.010_bib5","first-page":"32","article-title":"Polypharmacy: evaluating risks and deprescribing","volume":"100","author":"Halli-Tierney","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jamda.2022.06.010_bib6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.13876","article-title":"Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the Food and Drug Administration database","volume":"85","author":"Ruiter","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/0002512-200825120-00004","article-title":"Medication withdrawal trials in people aged 65 years and older: a systematic review","volume":"25","author":"Iyer","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jamda.2022.06.010_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bcp.12975","article-title":"The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis","volume":"82","author":"Page","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/CIRCRESAHA.118.313236","article-title":"Hypertension management in older and frail older patients","volume":"124","author":"Benetos","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jamda.2022.06.010_bib12","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J\u00a0Open Source Softw"},{"key":"10.1016\/j.jamda.2022.06.010_bib15","author":"Wickham"},{"key":"10.1016\/j.jamda.2022.06.010_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/14740338.2018.1397625","article-title":"A\u00a0narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms","volume":"17","author":"Reeve","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jamda.2022.06.010_bib18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2022.06.010_bib19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0012-3692(15)33392-4","article-title":"Safety of nitrate withdrawal in angina-free and hemodynamically stable patients with coronary artery disease","volume":"124","author":"George","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jamda.2022.06.010_bib20","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1532-5415.1999.tb07448.x","article-title":"Use of Valsalva\u2019s maneuver to detect early recurrence of congestive heart failure in a randomized trial of furosemide withdrawal in older patients","volume":"47","author":"van Kraaij","year":"1999","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jamda.2022.06.010_bib21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0002-9149(00)00795-5","article-title":"Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function","volume":"85","author":"van Kraaij","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jamda.2022.06.010_bib22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib23","doi-asserted-by":"crossref","first-page":"619088","DOI":"10.3389\/fphar.2021.619088","article-title":"Blood pressure changes following antihypertensive medication reduction, by drug class and dose chosen for withdrawal: exploratory analysis of data from the OPTiMISE trial","volume":"12","author":"Sheppard","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib24","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2020.01.040","article-title":"Withdrawal of neurohumoral blockade after cardiac resynchronization therapy","volume":"75","author":"Nijst","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2022.06.010_bib25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalsk\u00e1","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jamda.2022.06.010_bib27","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jamda.2022.06.010_bib28","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00198-017-4073-5","article-title":"Assessing the feasibility of the effectiveness of discontinuing bisphosphonates trial: a pilot study","volume":"28","author":"Wright","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jamda.2022.06.010_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jamda.2022.06.010_bib30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/art.20697","article-title":"Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis","volume":"51","author":"Cibere","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jamda.2022.06.010_bib31","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1185\/03007995.2015.1092127","article-title":"Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-na\u00efve patients with chronic pain","volume":"31","author":"Arai","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jamda.2022.06.010_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2022.06.010_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer\u2019s disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jamda.2022.06.010_bib34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease","volume":"366","author":"Howard","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156720511797633205","article-title":"Effects of galantamine in Alzheimer\u2019s disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment","volume":"8","author":"Gaudig","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jamda.2022.06.010_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer\u2019s disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.jamda.2022.06.010_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jamda.2015.08.019","article-title":"A\u00a0randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease","volume":"17","author":"Herrmann","year":"2016","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2022.06.010_bib38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2022.06.010_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","article-title":"Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa","volume":"65","author":"Biaggioni","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jamda.2022.06.010_bib40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jamda.2008.07.001","article-title":"The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism","volume":"9","author":"Tse","year":"2008","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2022.06.010_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.930040210","article-title":"Double-blind controlled withdrawal of thioridazine treatment in elderly female inpatients with senile dementia","volume":"4","author":"Findlay","year":"1989","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.2630","article-title":"6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer\u2019s disease","volume":"26","author":"Devanand","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib43","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer\u2019s disease","volume":"367","author":"Devanand","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1176\/appi.ajp.2016.16020226","article-title":"Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer\u2019s disease: the role of hallucinations","volume":"174","author":"Patel","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib45","doi-asserted-by":"crossref","first-page":"e1566","DOI":"10.1136\/bmj.e1566","article-title":"Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial","volume":"344","author":"Bergh","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2022.06.010_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00004714-199702000-00005","article-title":"Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression","volume":"17","author":"Hardy","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1192\/bjp.181.1.29","article-title":"Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy","volume":"181","author":"Klysner","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1192\/bjp.182.6.492","article-title":"Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study","volume":"182","author":"Wilson","year":"2003","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00228-003-0687-y","article-title":"Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression","volume":"59","author":"Ulfvarson","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s002280050213","article-title":"Gradual withdrawal from benzodiazepines in residents of homes for the elderly: experience and suggestions for future research","volume":"51","author":"Habraken","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib51","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1017\/S0033291703008213","article-title":"Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life","volume":"33","author":"Curran","year":"2003","journal-title":"Psychol Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/ajrccm.164.3.2002052","article-title":"Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction","volume":"164","author":"O\u2019Brien","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-8-93","article-title":"Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial","volume":"8","author":"Choudhury","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.jamda.2022.06.010_bib54","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00228-009-0697-5","article-title":"Seretide withdrawal increases airway inflammation in moderate COPD patients","volume":"65","author":"Borrill","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1164\/ajrccm.162.1.9909066","article-title":"Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial","volume":"162","author":"Rice","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/pros.2990170509","article-title":"Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial","volume":"3","author":"Fabricius","year":"1990","journal-title":"Prostate Suppl"},{"key":"10.1016\/j.jamda.2022.06.010_bib57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.jamda.2022.06.010_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1757-5672.2011.00109.x","article-title":"Effect of discontinuation of tamsulosin in Korean men with benign prostatic hyperplasia taking tamsulosin and dutasteride: an open-label, prospective, randomized pilot study","volume":"4","author":"Lee","year":"2012","journal-title":"LUTS Low Urin Tract Symptoms"},{"key":"10.1016\/j.jamda.2022.06.010_bib59","first-page":"905","article-title":"Effects of withdrawing \u03b11-blocker from combination therapy with \u03b11-blocker and 5\u03b1-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics","volume":"198","author":"Matsukawa","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jamda.2022.06.010_bib60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s41669-019-0167-7","article-title":"A\u00a0nationwide study of prevalence rates and characteristics of 199 chronic conditions in Denmark","volume":"4","author":"Hvidberg","year":"2020","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jamda.2022.06.010_bib61","first-page":"A12190680","article-title":"Prevalence of polypharmacy in Denmark","volume":"67","author":"Kornholt","year":"2020","journal-title":"Dan Med J"},{"key":"10.1016\/j.jamda.2022.06.010_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jclinepi.2020.07.011","article-title":"Describing deprescribing trials better: an elaboration of the CONSORT statement","volume":"127","author":"Blom","year":"2020","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jamda.2022.06.010_bib63","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0012-3692(15)33392-4","article-title":"Safety of nitrate withdrawal in angina-free and hemodynamically stable patients with coronary artery disease","volume":"124","author":"George","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jamda.2022.06.010_bib64","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1532-5415.1999.tb07448.x","article-title":"Use of Valsalva\u2019s maneuver to detect early recurrence of congestive heart failure in a randomized trial of furosemide withdrawal in older patients","volume":"47","author":"van Kraaij","year":"1999","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jamda.2022.06.010_bib65","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0002-9149(00)00795-5","article-title":"Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function","volume":"85","author":"van Kraaij","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jamda.2022.06.010_bib66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib67","doi-asserted-by":"crossref","first-page":"619088","DOI":"10.3389\/fphar.2021.619088","article-title":"Blood pressure changes following antihypertensive medication reduction, by drug class and dose chosen for withdrawal: exploratory analysis of data from the OPTiMISE trial","volume":"12","author":"Sheppard","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib68","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2020.01.040","article-title":"Withdrawal of neurohumoral blockade after cardiac resynchronization therapy","volume":"75","author":"Nijst","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2022.06.010_bib69","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib70","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalsk\u00e1","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jamda.2022.06.010_bib71","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jamda.2022.06.010_bib72","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jamda.2022.06.010_bib73","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jamda.2022.06.010_bib74","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00198-017-4073-5","article-title":"Assessing the feasibility of the effectiveness of discontinuing bisphosphonates trial: a pilot study","volume":"28","author":"Wright","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jamda.2022.06.010_bib75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jamda.2022.06.010_bib76","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib77","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/art.20697","article-title":"Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis","volume":"51","author":"Cibere","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jamda.2022.06.010_bib78","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1185\/03007995.2015.1092127","article-title":"Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-na\u00efve patients with chronic pain","volume":"31","author":"Arai","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jamda.2022.06.010_bib79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2022.06.010_bib80","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer\u2019s disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jamda.2022.06.010_bib81","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease","volume":"366","author":"Howard","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib82","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156720511797633205","article-title":"Effects of galantamine in Alzheimer\u2019s disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment","volume":"8","author":"Gaudig","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jamda.2022.06.010_bib83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer\u2019s disease: a randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer\u2019s disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.jamda.2022.06.010_bib85","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jamda.2015.08.019","article-title":"A\u00a0randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease","volume":"17","author":"Herrmann","year":"2016","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2022.06.010_bib86","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2022.06.010_bib87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","article-title":"Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa","volume":"65","author":"Biaggioni","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jamda.2022.06.010_bib88","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jamda.2008.07.001","article-title":"The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism","volume":"9","author":"Tse","year":"2008","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2022.06.010_bib89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.930040210","article-title":"Double-blind controlled withdrawal of thioridazine treatment in elderly female inpatients with senile dementia","volume":"4","author":"Findlay","year":"1989","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib90","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.2630","article-title":"6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer\u2019s disease","volume":"26","author":"Devanand","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib91","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer\u2019s disease","volume":"367","author":"Devanand","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib92","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1176\/appi.ajp.2016.16020226","article-title":"Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer\u2019s disease: the role of hallucinations","volume":"174","author":"Patel","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib93","doi-asserted-by":"crossref","first-page":"e1566","DOI":"10.1136\/bmj.e1566","article-title":"Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial","volume":"344","author":"Bergh","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2022.06.010_bib94","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00004714-199702000-00005","article-title":"Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression","volume":"17","author":"Hardy","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1192\/bjp.181.1.29","article-title":"Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy","volume":"181","author":"Klysner","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib96","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1192\/bjp.182.6.492","article-title":"Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study","volume":"182","author":"Wilson","year":"2003","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jamda.2022.06.010_bib97","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00228-003-0687-y","article-title":"Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression","volume":"59","author":"Ulfvarson","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib98","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s002280050213","article-title":"Gradual withdrawal from benzodiazepines in residents of homes for the elderly: experience and suggestions for future research","volume":"51","author":"Habraken","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib99","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1017\/S0033291703008213","article-title":"Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life","volume":"33","author":"Curran","year":"2003","journal-title":"Psychol Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/ajrccm.164.3.2002052","article-title":"Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction","volume":"164","author":"O\u2019Brien","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-8-93","article-title":"Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial","volume":"8","author":"Choudhury","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.jamda.2022.06.010_bib102","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00228-009-0697-5","article-title":"Seretide withdrawal increases airway inflammation in moderate COPD patients","volume":"65","author":"Borrill","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2022.06.010_bib103","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1164\/ajrccm.162.1.9909066","article-title":"Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial","volume":"162","author":"Rice","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jamda.2022.06.010_bib104","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/pros.2990170509","article-title":"Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial","volume":"3","author":"Fabricius","year":"1990","journal-title":"Prostate Suppl"},{"key":"10.1016\/j.jamda.2022.06.010_bib105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.jamda.2022.06.010_bib106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1757-5672.2011.00109.x","article-title":"Effect of discontinuation of tamsulosin in Korean men with benign prostatic hyperplasia taking tamsulosin and dutasteride: an open-label, prospective, randomized pilot study","volume":"4","author":"Lee","year":"2012","journal-title":"LUTS Low Urin Tract Symptoms"},{"key":"10.1016\/j.jamda.2022.06.010_bib107","first-page":"905","article-title":"Effects of withdrawing \u03b11-blocker from combination therapy with \u03b11-blocker and 5\u03b1-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics","volume":"198","author":"Matsukawa","year":"2017","journal-title":"J\u00a0Urol"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861022004686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861022004686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:29:28Z","timestamp":1761506968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861022004686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":103,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1525861022004686"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2022.06.010","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2022.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.","name":"copyright","label":"Copyright"}]}}